Compare FBP & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBP | TLX |
|---|---|---|
| Founded | 1948 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2010 | N/A |
| Metric | FBP | TLX |
|---|---|---|
| Price | $24.32 | $9.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $25.50 | $21.13 |
| AVG Volume (30 Days) | ★ 1.1M | 130.5K |
| Earning Date | 04-22-2026 | 08-19-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 18.78 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $1,255,034,000.00 | N/A |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $4.65 | N/A |
| P/E Ratio | ★ $42.63 | $150.33 |
| Revenue Growth | ★ 2.38 | N/A |
| 52 Week Low | $19.16 | $6.28 |
| 52 Week High | $24.64 | $17.25 |
| Indicator | FBP | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 41.14 |
| Support Level | $19.43 | $8.85 |
| Resistance Level | $24.57 | $9.92 |
| Average True Range (ATR) | 0.40 | 0.22 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 73.28 | 30.62 |
First BanCorp is a financial holding company. The company's operating segment includes Mortgage Banking; Consumer (Retail) Banking; Commercial and Corporate Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. The Consumer (Retail) Banking segment generates the majority of revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.